# Vaxart
Who / What
Vaxart, Inc. is an American biotechnology company specializing in the development of oral recombinant vaccines delivered via temperature-stable tablets that do not require refrigeration or needle injection. Its innovative Vector-Adjuvant-Antigen Standardized Technology (VAAST) aims to revolutionize vaccine administration by making them accessible through a convenient, non-invasive method.
Background & History
Founded within the context of advancing vaccine delivery methods, Vaxart focuses on oral vaccines for critical diseases such as norovirus, influenza, respiratory syncytial virus (RSV), and human papillomavirus (HPV). The company leverages its proprietary technology to create enteric-coated tablets that can be stored at room temperature, addressing logistical challenges in vaccine distribution. While specific founding details are not widely documented beyond its biotech focus, Vaxart has been active in the field of oral vaccination since its inception.
Why Notable
Vaxart’s innovation holds significant potential to transform global health by simplifying vaccine administration and reducing reliance on cold chain systems. Its approach could improve accessibility, especially in regions with limited infrastructure for refrigerated storage. The company’s work aligns with broader efforts to develop safer, more efficient vaccines, potentially making them a game-changer in public health strategies.
In the News
As of current data, Vaxart continues to advance its oral vaccine technology, targeting diseases like norovirus and influenza. Its progress is relevant due to ongoing discussions about improving vaccine delivery methods, particularly in response to challenges posed by global supply chain disruptions and the need for more resilient healthcare systems.
